During the past decade, gene therapy for the treatment of many inherited and acquired medical problems has become the subject of increasing focus in both the scientific litera ture and the lay press. This review examines the history and current status of gene therapy for advanced chronic periph eral and myocardial ischemia.
Get full access to this article
View all access options for this article.
References
1.
McGovern PG, Pankow JS, Shahar E., et al: Recent trends in acute coronary heart disease—Mortality, morbidity, medical care, and risk factors. N Engl J Med334:884-830, 1996
2.
Mendel GJ: Versuche über Pflanzen-Hybriden. Verh Neturf Vereins Brünn4:3-47, 1866
3.
Watson JD, Crick Fhc: Genetical implications of the structure of deoxyribonucleic acid. Nature171:964-969, 1953
4.
Avery OT, MacLeod CM, McCarty M: Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J Exp Med79:137-158, 1944
5.
Jackson DA, Symons R., Berg P.: Biochemical method for inserting new genetic information into DNA of simian virus 40: Circular SV40 DNA molecules containing Lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA69:2904-2909, 1872
6.
Nicolau C., LePape A., Soriano P., et al: In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I. Proc Natl Acad Sci USA80:1068-1072, 1983
7.
Nabel EG, Plautz G., Boyce FM, et al: Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science244:1342-1344, 1989
8.
Blaese RM, Culver KW, Miller AD, et al: T lymphocyte-directed gene therapy for ADA- SCID: Initial trial results after 4 years. Science270:475-480, 1995
9.
Isner JM, Walsh K., Symes J., et al: Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation91:2687-2692, 1995
10.
Leiden JM: Cytostatic gene transfer for vascular proliferative disorders. J Vasc Surg24:163, 1996
11.
Claudio PP , Fratta L., Farina F., et al: Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell praliferatian and prevents restenosis after angioplasty . Circ Res85:1032-1039, 1999
12.
Keating A., Toneguzzo F.: Gene transfer by electroporation: A model for gene therapy. Prog Clin Biol Res333:491-498, 1990
13.
Kato S., Anderson RA, Camerini-Otero RD: Foreign DNA introduced by calcium phosphate is integrated into repetitive DNA elements of the mouse L cell genome. Mol Cell Biol6:1787-1795, 1986
14.
Nabel EG, Yang Z., Liptay S., et al: Recombinant platelet-derived growth factor B gene expression in procine arteries induces intimal hyperplasia in vivo. J Clin Invest91:1822-1829, 1993
15.
Wilson JM, Grossman M., Wu CH, et al: Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low-density lipoprotein receptor-deficient rabbits. J Biol Chem267:963-967, 1992
16.
Turunen MP, Hiltunen MO, Ruponen M., et al: Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes. Gene Ther6:6-11, 1999
17.
Matsumura JS , Kim R., Shively VP, et al: Characterization of vascular gene transfer using a novel cationic lipid. J Surg Res85:339-345, 1999
18.
Kupfer JM, Ruan XM, Liu G., et al: High-efficiency gene transfer to autolagous rabbit jugular vein grafts using adenoviritstransferrin/polylysine-DNA complexes. Hum Gene Ther5: 1437-1443, 1994
19.
Geary RL, Clowes AW, Lau S., et al: Gene transfer in baboons using prosthetic vascular grafts seeded with retroviraliy transduced smooth muscle cells: A model for local and systemic gene therapy. Hum Gene Ther5:1211-1216. 1994
20.
Clowes MM, Lynch CM, Miller AD, et al: Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes . J Clin Invest93:644-651, 1994
21.
Lynch CM, Clowes MM, Osborne Wra, et al: Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: A model for gene therapy. Proc Natl Acad Sci USA89:1138-1142, 1992
22.
Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol10:4239-4242, 1990
23.
Donahue RE, Kessler SW, Bodine D., et al: Helper virus induced T cell lymphoma in nonhuman primate after retrokiral mediated gene transfer. J Exp Med176:1125, 1992
24.
Podsakoff G. , Wong KK, Chatterjee S.: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol68:5656-5666, 1994
25.
Svensson EC , Marshall DJ, Woodard K., et al: Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation99:201-205, 1999
26.
Kaplitt MG, Xiao X., Samulski RJ, et al: Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann Thorac Surg62:1669-1676, 1996
27.
Rolling F., Nong Z., Pisvin S., et al: Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther4:757-761, 1997
28.
Gnatenko D. , Arnold TE, Zolotukhin S., et al: Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells . Invest Med45:87-98. 1997
29.
Arnold TE, Gnatenko D., Bahou WF: In vivo gene transfer into rat arterial walls with novel adeno-associated virus vectors. J Vasc Surg25:347-355, 1997
30.
Lynch CM, Hara PSLeonard JC, et al: Adeno-associated virus vectors for vascular gene delivery. Circ Res80:497-505, 1997
31.
Maeda Y., Ikeda U., Ogasawara Y., et al: Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. Cardiovasc Res35:514-521, 1997
32.
Stevens JG, Wagner EK, Devi-Rao GB, et al: RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science235:1056-1059, 1987
33.
Key MS, Vercellotti GM, Winkelmann JC, et al: Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression . Proc Natl Acad Sci USA87:7095-7099, 1990
Guzman RJ, Lemarchand P., Crystal RG, et al: Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation88:2838-2848, 1993
36.
Chang MW, Ohno T., Gorson D., et al: Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Mol Med1:172-181, 1995
37.
Dichek D., Schneider DB, Newman KD: Modification of the vascular phenotype by viral gene transfer: Therapy and toxicity. J Vasc Surg24:163-165, 1996
38.
Lemarchand P., Jones M., Yamada I., et al: In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res72:1132-1138, 1993
39.
Schneider DB , Sassani AB, Vassalli G., et al: Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors. J Vasc Surg29:543-550, 1999
40.
Engelhardt JF, Ye X., Doranz B., et al: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA91:6196-6200, 1994
41.
Kay M.: Adenoviral vectors: Promises and pitfalls. J Vasc Surg24:160-161, 1996
42.
Laitinen M. , Mäkinen K., Manninen H., et al: Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther9:1481-1486, 1998
43.
Nabel EG, Plautz G., Nabel GJ: Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science249:1285-1288, 1990
44.
Rome JJ, Shayani V., Newman KD, et al: Adenoviral vector-mediated gene transfer into sheep arteries using a double-balloon catheter. Hum Gene Ther5:1249-1258, 1994
45.
Fram DB, Aretz T., Azrin MA, et al: Localized intramural drug delivery during balloon angioplasty using hydrogel coated balloons and pressure-augmented diffusion. J Am Coll Cardiol23:1570-1577, 1994
46.
Chapman GD, Lim CS, Gammon RS, et al: Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res71:27-33, 1992
47.
Tahlil O., Brami M., Feldman LJ, et al: The Dispatch catheter as a delivery tool for arterial gene transfer . Cardiovasc Res33:181-187, 1997
48.
Eigler NL: Local release of bioactive substances from metallic stents. J Vasc Surg24:171-172, 1996
49.
Lambert TL, Dev V., Rechavia E., et at: Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Circulation90:1003-1011, 1994
50.
Murphy JG, Schwartz RS, Edwards WD, et al: Percutaneous polymeric stents in porcine coronary arteries: Initial experience with polyethylene terephthalate stents. Circulation86: 1596-1604, 1992
51.
Eberhart R. : Genetic modification of intravascular stents . J Vasc Surg24:173, 1996
52.
Moawad J., Schwartz LB, Gewertz BL, et al: Efficiency of adenoviral-mediated gene transfer in experimental vein grafts. Presented at the Midwestern Vascular Surgery Society, Chicago, IL, September 17, 1997
53.
Quax Pha, Lamfers Mlm, Grimbergen J., et al: Effects of adenoviral infection on umbilical vein endothelial and smooth muscle cells. J Vasc Res33:320, 1996 (abstr, suppl 1)
54.
Channon KM, Fulton GJ, Gray JL, et al: Efficient adenoviral gene transfer to early venous bypass grafts: Comparison with native vessels. Cardiovasc Res35:505-513, 1997
55.
Mann MJ, Whittemore AD, Donaldson MC, et al: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet354:1493-1498, 1999
56.
Califf RM, Fortin DF, Fried DJ, et al: Restenosis after coronary angioplasty: An overview. J Am Coll Cardiol17:2B-13B, 1991
57.
Gray BH, Sullivan TM, Childs MB, et al: High incidence of restenosis/reocclusion of intravascular stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg25:74-83, 1997
58.
Stanley B., Teague B., Raptis S., et al: Efficacy of balloon angioplasty of the superficial femoral artery and popliteal artery in the relief of leg ischemia. Vase Surg23:679-685, 1996
59.
Libby P., Schwartz D., Brogi E., et al: A cascade model for restenosis: A special case of atherosclerosis progression. Circulation86:III-47-III-52, 1992 (suppl 3)
60.
Liu MW, Roubin GS, King SB, III: Restenosis after coronary angioplasty: Potential biologic determinants and role of intimal hyperplasia. Circulation79:1374-1387, 1989
61.
Schwartz SM , deBlois D., O'Brien Erm: The intima: Soil for atherosclerosis and restenosis. Circ Res77:445-465, 1995
62.
Bennett MR, Schwartz SM: Antisense therapy for angioplasty restenosis: Some critical considerations . Circulation92:1981-1993, 1995
63.
Mintz GS, Popma JJ, Pichard AD, et al: Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation94:35-43, 1996
64.
Currier JW, Faxon DP: Restenosis after percutaneous transluminal coronary angioplasty: Have we been aiming at the wrong target?J Am Coll Cardiol25:516-520, 1995
65.
Loscalzo J. : Vascular matrix and vein graft failure: Is the message in the medium. Circulation101:221-223, 2000
66.
Schwartz RS , Holmes DR, Jr, Topol EJ: The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Coll Cardiol20:1284-1293, 1992
67.
Chang MW, Barr E., Lu MM, et al: Adenovirus-mediated over-expression of the cvclinjcvclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty . J Clin Invest95:2260-2268, 1995
68.
Wang CY, Petryniak B., Thompson CB, et al: Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. Science260:1330-1335, 1993
69.
Hollingsworth RE, Jr, Hensey CE, Lee WH: Retinoblastoma protein and the cell cycle . Curr Opin Genet Dev3:55-62, 1993
70.
Chen PL, Scully P., Shew JY, et al: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell58:1193-1198, 1989
71.
Braun-Dullaeus RC, Mann MJ, Dzau VJ: Cell cycle progression: New therapeutic target for vascular proliferative disease. Circulation98:82-89, 1998
Ohno T., Gordon D., San H., et al: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science265:781-784, 1994
74.
Plautz G., Nabel EG, Nabel GJ: Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation83:578-583, 1991
75.
Lee SW, Trapnell BC, Rade JJ, et al: In vivo adenovral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res73:797-807, 1993
76.
Riessen R., Rahimizadeh H., Blessing E., et al: Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther4:749-758, 1993
77.
Willard JE, Landau C., Glamann B., et al: Genetic modification of the vessel wall: Comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation89:2190-2197, 1994
78.
Lim CS, Chapman GD, Gammon RS, et al: Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog. Circulation83:2007-2011, 1991
79.
Leclerc G., Gal D., Takeshita S., et al: Percutaneous arterial gene transfer in a rabbit model. J Clin Invest90:936-944, 1992
80.
French BA, Mazur W., Ali NM, et al: Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models ofrestenosis. Circulation90:2402-2413, 1994
81.
Rolling F., Nong Z., Pisvin S., et al: Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther4:757-761, 1997
82.
Feldman HJ, Pastore CJ, Aubailly N., et al: Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Gene Ther4:189-198, 1997
83.
Kaye FJ, Kratzke RAGerster JL, et al: A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc Natl Acad Sci USA87:6922-6926, 1990
84.
Smith RC, Wills KN, Antelman D., et al: Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation96:1899-1905, 1997
85.
Chang MW, Barr E., Seltzer J., et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science267:518-522,1995
86.
Schwartz LB , Moawad J.Svensson EC, et al: Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J Vasc Surg29:874-883, 1999
87.
De Geest B., Zhao Z., Collen D., et al: Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation96:4349-4356, 1997
88.
Ueno H., Haruno A., Morisaki N., et al: Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/ paracrine loop. Circulation96:2272-2279, 1997
89.
Chemla E., Castier Y., Julia P., et al: Inhibition of intimal hyperplasia by an antisense oligonucleotide of farnesyl transferase delivered endoluminally during iliac angioplasty in a rabbit model. Ann Vasc Surg11:581-587, 1997
90.
Maillard L. , Van Belle E, Smith RC, et al: Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc Res35:536-546, 1997
91.
Smith RC, Branellec D., Gorski DH, et al: p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev11:1674-1689, 1997
92.
Hanna AK, Fox JC, Neschis DG, et al: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg25:320-325, 1997
93.
Neschis DG, Safford SD, Hanna AK, et al: Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. J Vasc Surg27:126-134. 1998
94.
Steg PG, Tahlil O., Aubailly N., et al: Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation96:408-411, 1997
95.
Fortunato JE , Mauceri HJ, Kocharyan H., et al: Gene therapy enhances the antiproliferative effect of radiation in intimal hyperplasia. J Surg Res89:155-162, 2000
96.
Harrell RL, Rajanayagam S., Doanes AM, et al: Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase . Circulation96:621-627, 1997
97.
Zhu NL, Wu L., Liu PX, et al: Downregulation of cyclin Gl expression by retrovirus-medtated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation96:628-635, 1997
98.
Murakami H. , Yayama K., Miao RQ et al: Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension34:164-170, 1999
99.
Dichek DA, Neville RF, Zwiebel JA, et al: Seeding of intravascular stents with genetically engineered endothelial cells. Circulation80:1347-1353, 1989
100.
Van Belle E , Tio FO, Chen D., et al: Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol29:1371-1379, 1997
101.
DeWeese JA , Leather R., Porter J.: Practice guidelines: Lower extremity revascularization . J Vasc Surg18:280-294, 1993
102.
Myler RK, Stertzer SH: Coronary and peripheral angioplasty: Historical perspective, in Topol EJ (ed): Textbook of Interventional Cardiology. vol 2. Philadelphia, PA, Saunders, 1994, pp 171-185
103.
Bourassa MG, Fisher LD, Campeau L., et al: Long-term fate of bypass grafts: The Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences. Circulation72:V-71-V-78, 1985 (suppl 5)
104.
Lytle BW, Loop FD, Cosgrove DM, et al: Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg89:248-258, 1985
105.
Donaldson MC, Whittemore AD, Mannick JA: Further experience with an all-autogenous tissue policy for infrainguinal reconstruction. J Vasc Surg18:41-48. 1993
106.
Bergamini TM, George SM, Jr, Massey HT, et al: Intensive surveillance of femoropopliteal-tibial autogenous vein bypasses improves long-term graft patency and limb salvage. Ann Surg221:507-516. 1995
107.
Donaldson MC, Mannick JA, Whittemore AD: Causes of primary graft failure after in situ saphenous vein bypass grafting. J Vasc Surg15:113-120, 1992
Cox JL, Chiasson DA, Gotlieb AI: Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries . Prog Cardiovasc Dis1:45-68. 1991
110.
Schwartz LB , Pence JC, Kerns BJ, et al: Kinetics of experimental vein graft cell division and function. Surg Forum27:363-365, 1991
111.
Golden MA: Modification of vein graft adaptation using adenoviral vectors. J Vasc Surg24:161-163, 1996
112.
Chen S., Wilson JM, Muller Dwm: Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation89:1922-1928, 1994
113.
Mann MJ, Gibbons GH, Hutchinson H., et al: Effective antisense oligonucleotide transfection in human saphenous vein for the development of genetically engineered bypass grafts. Circulation92:1-642, 1995 (suppl 1)
114.
Mann MJ, Gibbons GH, Kemoff RS, et al: Genetic engineering of vein grafts resistant to atherosclerosis . Proc Natl Acad Sci USA92:4502-4506, 1995
115.
Hong-zhi B. , Yoshiki S., Tomoyuki Y., et al: Gene transfer of senescent cell-derived inhibitor 1 into vein graft inhibited neointimal hyperplasia in vivo associated with induction of smooth muscle cell redifferentiation. Circulation92:I-642, 1995 (suppl 1)
116.
Matsushita H., Morishita R., Kida I., et al: Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis . Hypertension31 (1 Pt 2):493-498, 1998
117.
Fulton GJ, Davies MG, Lefkowitz RJ, et al: Transfection with βARKCT reduces intimal hyperplasia in experimental vein grafts. Surg Forum47:341-345, 1996
118.
Quax Pha, Lamfers ML, Grimbergen JG, et al: Inhibition of neointima formation in cultured human saphenous vein segments by an adenovirus expressing an urokinase receptor binding plasmin inhibitor. Circulation96:1-669, 1997 (abstr, suppl 1)
119.
Fulton GJ, Davies MG, Koch WJ, et al: Antisense oligonucleotide to proto-oncogene c-myb inhibits the formation of intimal hyperplasia in experimental vein grafts. J Vasc Surg25:453-463, 1997
120.
Baker A., George A., Angelini G., et al: Tissue inhibitor of mellatoproteinase-2 overexpression inhibits neointima formation inhuman saphenous vein organ cultures. Am Soc Gene Ther1:65a, 1998 (abstr)
121.
Matsumoto T., Komori K., Yonemitsu Y., et al: Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg27:135-144, 1998
122.
Mann MJ, Whittemore AD, Donaldson MC, et al: Preliminary clinical experience with genetic engineering of human vein grafts: Evidence for target gene inhibition. Circulation1997; 96:1-4, 1997 (abstr, suppl 1)
123.
Morishita R., Gibbons GH, Horiuchi M., et al: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA92:5855-5859, 1995
124.
Folkman J. : Tumor angiogenesis: Therapeutic implications . N Engl J Med285:1182-1186, 1971
125.
Pepper MS: Positive and negative regulation of angiogenesis: From cell biology to the clinic. Vasc Med1:259-266, 1996
126.
Safi J., Jr, Gloe TR, Riccioni T., et al: Gene therapy with angiogenic factors: A new potential approach to the treatment of ischemie diseases. J Mol Cell Cardiol29:2311-2325, 1997
127.
Isner JM: Therapeutic angiogenesis: A new frontier for vascular therapy. Vasc Med1:79-87, 1996
128.
Asahara T. , Bauters C., Pastore C., et al: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation91:2793-2801, 1995
129.
Lee LY, Patel SR, Hackett NR, et al: Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg69:14-23, 2000
130.
Lazarous DF , Shou M., Scheinowitz M., et al: Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation94:1074-1082, 1996
131.
Hopkins SP , Bulgrin JP, Sims RL, et al: Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia. J Vasc Surg27:886-895, 1998
132.
Tsurumi Y. , Takeshita S., Chen D., et al: Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation94:3281-3290, 1996
133.
Mack CA, Magovern CJ, Budenbender KT, et al: Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion . J Vasc Surg27:699-709, 1998
134.
Magovern CJ , Mack CA, Zhang J., et al: Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor . Hum Gene Ther8:215-227, 1997
135.
Mülhauser J., Pili R., Merrill MJ, et al: In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Hum Gene Ther6:1457-1465, 1995
136.
Ueno H., Li JJ, Masuda S., et al: Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol17:2453-2460, 1997
137.
Tabata H., Silver M., Isner JM: Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: Critical role of secretion signal in use of naked DNA . Cardiovasc Res35:470-479, 1997
138.
Baumgartner I., Pieczek A., Manor O., et al: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation97:1114-1123, 1998
139.
Isner JM, Pieczek A., Schainfeld R., et al: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet348:370-374, 1996
140.
Schumacher B., Pecher P., von Specht BU, et al: Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation97:645-650, 1998
141.
Folkman J. : Angiogenic therapy of the human heart. Circulation97:628-629, 1998
142.
Symes JF, Losordo DW, Vale PR, et al: Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg68:830-836, 1999
143.
Rosengart TK, Lee LY, Patel SR, et al: Angiogenesis gene therapy phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation100:468-474, 1999
144.
Laitinen M. , Makinen K., Manninen H., et al: Adenovirus-mediated B-galactosidase gene transfer to lower limb artery of patients with critical limb ischemia . Circulation96:I-483, 1997 (suppl 1)
145.
Meyerson SL , Schwartz, LB: Gene therapy as a therapeutic intervention for vascular disease. J Cardiovasc Nurs13:91-109, 1999
